Lancet Microbe最新文献

筛选
英文 中文
Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme. 接种肺炎球菌结合疫苗对蒙古 2-59 个月住院儿童肺炎球菌携带率的影响:一项积极的肺炎监测计划。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-29 DOI: 10.1016/S2666-5247(24)00171-X
Claire von Mollendorf, Tuya Mungun, Munkhchuluun Ulziibayar, Cattram D Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Belinda D Ortika, Casey L Pell, Ashleigh Wee-Hee, Monica L Nation, Jason Hinds, Eileen M Dunne, E K Mulholland, Catherine Satzke
{"title":"Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme.","authors":"Claire von Mollendorf, Tuya Mungun, Munkhchuluun Ulziibayar, Cattram D Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Belinda D Ortika, Casey L Pell, Ashleigh Wee-Hee, Monica L Nation, Jason Hinds, Eileen M Dunne, E K Mulholland, Catherine Satzke","doi":"10.1016/S2666-5247(24)00171-X","DOIUrl":"https://doi.org/10.1016/S2666-5247(24)00171-X","url":null,"abstract":"<p><strong>Background: </strong>Data on changes in pneumococcal serotypes in hospitalised children following the introduction of the pneumococcal conjugate vaccine (PCV) in low-income and middle-income countries are scarce. In 2016, Mongolia introduced the 13-valent PCV (PCV13) into the national immunisation programme. We aimed to describe the trend and impact of PCV13 introduction on pneumococcal carriage in hospitalised children aged 2-59 months with pneumonia in Mongolia over a 6-year period.</p><p><strong>Methods: </strong>In this active surveillance programme, children aged 2-59 months with pneumonia who met the study case definition (cough or difficulty breathing with either respiratory rate ≥50 beats per min, oxygen saturation <90%, or clinical diagnosis of severe pneumonia) were enrolled between April 1, 2015, and June 30, 2021, from four districts in Ulaanbaatar. We tested nasopharyngeal samples collected at enrolment for pneumococci using lytA real-time quantitative PCR and conducted molecular serotyping and detection of antimicrobial resistance (AMR) genes with DNA microarray. We used log-binomial regression to estimate prevalence ratios (PRs) of pneumococcal carriage, comparing prevalence in the periods before and after the introduction of PCV13 and between vaccinated and unvaccinated children for three outcomes: overall, PCV13 vaccine-type, and non-PCV13 vaccine-type carriage. PRs were adjusted with covariates that were identified by use of a directed acyclic graph, informed by relevant literature.</p><p><strong>Findings: </strong>A total of 17 688 children were enrolled, of whom 17 607 (99·5%) met the study case criteria. 6545 (42·5%) of 15 411 collected nasopharyngeal swabs were tested for pneumococci. In all age groups, a similar prevalence of pneumococcal carriage was shown between the pre-PCV13 period and post-PCV13 period (882 [48·0%] of 1837 vs 2174 [46·2%] of 4708; adjusted PR 0·98 [95% CI 0·92-1·04]; p=0·60). Overall, vaccine-type carriage reduced by 43·6% after the introduction of PCV13 (adjusted PR 0·56 [95% CI 0·51-0·62]; p<0·0001). Younger children (aged 2-23 months) showed a 47·7% reduction in vaccine-type carriage (95% CI 41·2-53·5; adjusted PR 0·52 [95% CI 0·46-0·59]; p<0·0001), whereas children aged 24-59 months had a 29·3% reduction (12·6-42·8; 0·71 [0·57-0·87]; p=0·0014). Prevalence of 6A, 6B, 14, 19F, and 23F decreased following the introduction of PCV13; however, 19F and 6A remained common (5·8% and 2·9%). Non-vaccine-type carriage increased (adjusted PR 1·49 [95% CI 1·32-1·67]), with 15A, NT2, and 15B/C being the most prevalent serotypes. Overall, 1761 (89·3%) of 1978 analysed samples contained at least one AMR gene. The percentage of samples with any AMR gene decreased with vaccine introduction (92·3% in the pre-PCV13 period vs 85·3% in the post-PCV13 period; adjusted odds ratio 0·49 [95% CI 0·34-0·70]), with similar decreases for samples with at least three AMR genes (46·8% vs 27·6%; 0·44 [0·36-0·55]).</p><p><","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Saliva as a reliable, non-invasive specimen for detecting and monitoring Mycobacterium leprae. 唾液是检测和监测麻风分枝杆菌的可靠、无创标本。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-25 DOI: 10.1016/j.lanmic.2024.101014
Xi Yang, Zhengfang Wang, Yuliang Qin, Chiyu Zhang, Yu-Ye Li
{"title":"Saliva as a reliable, non-invasive specimen for detecting and monitoring Mycobacterium leprae.","authors":"Xi Yang, Zhengfang Wang, Yuliang Qin, Chiyu Zhang, Yu-Ye Li","doi":"10.1016/j.lanmic.2024.101014","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101014","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood transcriptomic analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19 condition with chronic fatigue syndrome. 血液转录组分析不支持 SARS-CoV-2 在 COVID-19 后慢性疲劳综合征患者中的持续存在。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-25 DOI: 10.1016/j.lanmic.2024.101012
Amirhossein Rahmati, Shima Shahbaz, Mohammed Osman, Jan Willen Cohen Tervaert, Shokrollah Elahi
{"title":"Blood transcriptomic analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19 condition with chronic fatigue syndrome.","authors":"Amirhossein Rahmati, Shima Shahbaz, Mohammed Osman, Jan Willen Cohen Tervaert, Shokrollah Elahi","doi":"10.1016/j.lanmic.2024.101012","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101012","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endocarditis associated with contamination of cardiovascular bioprostheses with Mycobacterium chelonae: a collaborative microbiological study. 与心血管生物假体被螯合分枝杆菌污染有关的心内膜炎:一项微生物学合作研究。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-24 DOI: 10.1016/j.lanmic.2024.06.001
Judith Kikhney, Inna Friesen, Solveigh Wiesener, Laura Kursawe, Christoph Loddenkemper, Josef Zündorf, Beate Häuser, Esther P Cónsul Tejero, Dinah V Schöning, Kurosh Sarbandi, Doris Hillemann, Martin Kuhns, Miriam S Stegemann, Frieder Pfäfflin, Frank-Rainer Klefisch, Volker Düsterhöft, Sebastian Haller, Anja V Laer, Tim Eckmanns, Emmanuelle Cambau, Sarah Tschudin-Sutter, Barbara Hasse, Anette Friedrichs, Bernd Panholzer, Walter Eichinger, Petra Gastmeier, Volkmar Falk, Annette Moter
{"title":"Endocarditis associated with contamination of cardiovascular bioprostheses with Mycobacterium chelonae: a collaborative microbiological study.","authors":"Judith Kikhney, Inna Friesen, Solveigh Wiesener, Laura Kursawe, Christoph Loddenkemper, Josef Zündorf, Beate Häuser, Esther P Cónsul Tejero, Dinah V Schöning, Kurosh Sarbandi, Doris Hillemann, Martin Kuhns, Miriam S Stegemann, Frieder Pfäfflin, Frank-Rainer Klefisch, Volker Düsterhöft, Sebastian Haller, Anja V Laer, Tim Eckmanns, Emmanuelle Cambau, Sarah Tschudin-Sutter, Barbara Hasse, Anette Friedrichs, Bernd Panholzer, Walter Eichinger, Petra Gastmeier, Volkmar Falk, Annette Moter","doi":"10.1016/j.lanmic.2024.06.001","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.06.001","url":null,"abstract":"<p><strong>Background: </strong>Mycobacterium chelonae is a rare cause of infective endocarditis that is difficult to diagnose and treat. After we found M chelonae in a series of patients, we aimed to investigate its role in cardiovascular prosthesis dysfunction and contamination of bioprostheses as a possible cause of infection.</p><p><strong>Methods: </strong>In this collaborative microbiological study, we report on nine patients treated in three cardiovascular surgical departments in Germany, who were found to have M chelonae infection after receiving BioIntegral bioprostheses. We performed fluorescence in-situ hybridisation (FISH) combined with broad-range 16S rRNA gene amplification and sequencing (FISHseq) on samples of native cardiovascular tissue and explanted bioprosthetic material, as well as on 12 unused BioIntegral prostheses. We confirmed FISHseq findings with histological examination by staining for acid-fast bacilli, and M chelonae was differentiated from M abscessus by molecular techniques.</p><p><strong>Findings: </strong>Between Dec 1, 2020, and Feb 28, 2022, we identified M chelonae in BioIntegral bioprostheses from three initial patients treated in Berlin that were explanted following dysfunction or suspected endocarditis, visualising morphologically intact FISH-positive mycobacteria. Despite negative mycobacterial culture, we also detected M chelonae in all 12 unused BioIntegral prostheses. The competent authorities in the EU prompted an alert, leading to the identification of six additional patients between March 1, 2022, and July 31, 2023. To find other cases of M chelonae endocarditis, we reviewed the FISHseq results of 1237 cardiovascular samples that were analysed between Jan 1, 2015, and Aug 31, 2022, including 295 samples from 228 bioprostheses supplied by other manufacturers. M chelonae was only detected in six of 41 patients who had received BioIntegral products.</p><p><strong>Interpretation: </strong>Bioprostheses manufactured by BioIntegral Surgical might be colonised by M chelonae, which can lead to implant dysfunction. These infections are likely to be missed by conventional routine diagnostics and should be considered in patients with BioIntegral implants and suspected infection or dysfunction. Cases should be reported to public health and regulatory authorities. Routine safety testing of bioprostheses during manufacture should be reconsidered.</p><p><strong>Funding: </strong>German Federal Ministry of Education and Research.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses. 解决抗生素开发中的当务之急:世界卫生组织 2023 年抗菌药物临床管线分析的启示。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-22 DOI: 10.1016/j.lanmic.2024.100992
Daniela Melchiorri, Tamarie Rocke, Richard A Alm, Alexandra M Cameron, Valeria Gigante
{"title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.","authors":"Daniela Melchiorri, Tamarie Rocke, Richard A Alm, Alexandra M Cameron, Valeria Gigante","doi":"10.1016/j.lanmic.2024.100992","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.100992","url":null,"abstract":"<p><p>Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic epidemiology of Salmonella: the need to consider vaccination history and nutritional status in resistance transmission studies. 沙门氏菌基因组流行病学:在耐药性传播研究中需要考虑疫苗接种史和营养状况。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-22 DOI: 10.1016/j.lanmic.2024.101011
Lianwei Zhou, Minye Wang, Wenbo Li
{"title":"Genomic epidemiology of Salmonella: the need to consider vaccination history and nutritional status in resistance transmission studies.","authors":"Lianwei Zhou, Minye Wang, Wenbo Li","doi":"10.1016/j.lanmic.2024.101011","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101011","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial. 美国对住院疑似肺炎患者进行肺炎快速多重 PCR 检测:单中心、开放标签、实用随机对照试验。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-16 DOI: 10.1016/S2666-5247(24)00170-8
Abinash Virk, Angel P Strasburg, Kami D Kies, Alexander D Donadio, Jay Mandrekar, William S Harmsen, Ryan W Stevens, Lynn L Estes, Aaron J Tande, Douglas W Challener, Douglas R Osmon, Madiha Fida, Paschalis Vergidis, Gina A Suh, John W Wilson, Nipunie S Rajapakse, Bijan J Borah, Ruchita Dholakia, Katelyn A Reed, Lisa M Hines, Audrey N Schuetz, Robin Patel
{"title":"Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial.","authors":"Abinash Virk, Angel P Strasburg, Kami D Kies, Alexander D Donadio, Jay Mandrekar, William S Harmsen, Ryan W Stevens, Lynn L Estes, Aaron J Tande, Douglas W Challener, Douglas R Osmon, Madiha Fida, Paschalis Vergidis, Gina A Suh, John W Wilson, Nipunie S Rajapakse, Bijan J Borah, Ruchita Dholakia, Katelyn A Reed, Lisa M Hines, Audrey N Schuetz, Robin Patel","doi":"10.1016/S2666-5247(24)00170-8","DOIUrl":"https://doi.org/10.1016/S2666-5247(24)00170-8","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The clinical utility of rapid multiplex respiratory specimen PCR panels for pneumonia for patients with suspected pneumonia is undefined. We aimed to compare the effect of the BioFire FilmArray pneumonia panel (bioMérieux, Salt Lake City, UT, USA) with standard of care testing on antibiotic use in a real-world hospital setting.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a single-centre, open-label, pragmatic, randomised controlled trial at the Mayo Clinic, Rochester, MN, USA. Hospitalised patients (aged ≥18 years) with suspected pneumonia, from whom expectorated or induced sputum, tracheal secretions, or bronchoalveolar lavage fluid respiratory culture samples (one per individual) could be collected during index hospitalisation, were eligible for inclusion. Samples from eligible participants were randomly assigned (1:1) with a computerised tool to undergo testing with either the BioFire FilmArray pneumonia panel, conventional culture, and antimicrobial susceptibility testing (intervention group) or conventional culture and antimicrobial susceptibility testing alone (control group). Antimicrobial stewardship review in both groups involved an assessment and recommendations for antibiotic modifications based on clinical data and the results from the BioFire FilmArray pneumonia panel, conventional culture, or both. The primary outcome was median time to first antibiotic modification (ie, escalation or de-escalation of antibiotics against Gram-negative and Gram-positive bacteria) within 96 h of randomisation, assessed with the Wilcoxon rank-sum test and analysed in a modified intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT05937126).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Sept 15, 2020, and Sept 19, 2022, 1547 patients were screened for eligibility, of whom 1181 (76·3%) were randomly assigned: 582 (49·3%) to the intervention group and 599 (50·7%) to the control group. In total, 1152 participants were included in the modified intention-to-treat analysis, 589 (51·1%) in the control group and 563 (48·9%) in the intervention group. For the modified intention-to-treat population, median time to any first antibiotic modification was 20·4 h (95% CI 18·0-20·4) in the intervention group and 25·8 h (22·0-28·7) in the control group (p=0·076). Median time to any antibiotic escalation was 13·8 h (9·2-19·0) in the intervention group and 24·1 h (19·5-29·6) in the control group (p=0·0022). Median time to escalation of antibiotics against Gram-positive organisms was 10·3 h (6·2-30·9) in the intervention group and 24·6 h (19·5-37·2) in the control group (p=0·044); median time to escalation of antibiotics against Gram-negative organisms was 17·3 h (10·8-23·3) in the intervention group and 27·2 h (21·3-33·9) in the control group (p=0·010). Median time to any antibiotic de-escalation did not differ between groups (p=0·37). Median time to first de-escalation of antibiotics against Gram-positive organis","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viral concentrations in unpasteurised milk from avian influenza-infected cattle. 受禽流感感染的牛的未消毒牛奶中的病毒浓度。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-15 DOI: 10.1016/j.lanmic.2024.101009
Amir Ghaemi
{"title":"Viral concentrations in unpasteurised milk from avian influenza-infected cattle.","authors":"Amir Ghaemi","doi":"10.1016/j.lanmic.2024.101009","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101009","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intersection of artificial intelligence, microbes, and bone and joint infections: a new frontier for improving management outcomes. 人工智能、微生物与骨关节感染的交叉:改善管理成果的新领域。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-15 DOI: 10.1016/j.lanmic.2024.101008
Mohamed A Imam, Atef Abdelrahman, Adam Zumla, Rizwan Ahmed, Giovanni Satta, Alimuddin Zumla
{"title":"Intersection of artificial intelligence, microbes, and bone and joint infections: a new frontier for improving management outcomes.","authors":"Mohamed A Imam, Atef Abdelrahman, Adam Zumla, Rizwan Ahmed, Giovanni Satta, Alimuddin Zumla","doi":"10.1016/j.lanmic.2024.101008","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101008","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of an all-in-one pan-sarbecovirus ferritin nanoparticle vaccine in humans. 在人体中开发一体化泛沙巴病毒铁蛋白纳米粒子疫苗。
IF 20.9 1区 生物学
Lancet Microbe Pub Date : 2024-10-14 DOI: 10.1016/j.lanmic.2024.100974
Liuying Li, Hao Zhou
{"title":"Development of an all-in-one pan-sarbecovirus ferritin nanoparticle vaccine in humans.","authors":"Liuying Li, Hao Zhou","doi":"10.1016/j.lanmic.2024.100974","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.100974","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信